Compile Data Set for Download or QSAR
Report error Found 62 Enz. Inhib. hit(s) with all data for entry = 11073
TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298285(US11547687, Example 2A | US11547687, Compound Exam...)
Affinity DataKi:  0.200nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582848(US11547687, Comparative Compound J | US20230285340...)
Affinity DataKi:  0.316nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582849(US11547687, Comparative Compound K)
Affinity DataKi:  0.501nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298305(US11547687, Compound Example 5A | US10123984, Exam...)
Affinity DataKi:  0.631nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298295(US20230285340, Example 3A | US10123984, Example 3D...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298294(US11547687, Example 2V | US10744104, Example 2V | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582645(US11547687, Example 5-13)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298285(US11547687, Example 2A | US11547687, Compound Exam...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458421(US10744104, Example 14A | US11547687, Example 14A ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582706(US11547687, Example 3D)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582656(US11547687, Example 5-17)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582718(US11547687, Example 5-5)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298305(US11547687, Compound Example 5A | US10123984, Exam...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582719(US11547687, Example 5-9)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582648(US11547687, Example 5-14)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582710(US11547687, Example 5-1)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582655(US11547687, Example 5-15)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298288(US11547687, Example 2H | US10123984, Example 2H | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298306(US10123984, Example 7B | US11547687, Example 7B)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298286(US11547687, Example 2F | US10744104, Example 2F | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582669(US11547687, Example 8-2)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458409(US10744104, Example 7B | US11547687, Example 8-3 |...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298291(US10123984, Example 2N | US11547687, Example 2N | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582844(US11547687, Comparative Compound G | US20230285340...)
Affinity DataKi:  1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582685(US11547687, Example 11-2)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298293(US11547687, Example 2U | US10744104, Example 2U | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298292(US10123984, Example 2T | US10744104, Example 2T | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582845(US11547687, Comparative Compound H | US20230285340...)
Affinity DataKi:  2.51nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582704(US11547687, Example 13)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298322(US10123984, Example 14A | US10123984, Example 14F ...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298297(US10123984, Example 4 | (2R,4R)-5-(3-Chlorobipheny...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458423(US10744104, Example 14F | US11547687, Example 14F ...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298287(US11547687, Example 2G | US10744104, Example 2G | ...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298326(US10123984, Example 16 | US10744104, Example 16 | ...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298289(US10744104, Example 2I | US11547687, Example 2I | ...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458412(US10744104, Example 8-4 | US11547687, Example 8-4)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582673(US11547687, Example 8-5)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298315(US11547687, Example 11-1 | US10744104, Example 10 ...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298312(US10123984, Example 9A | US10744104, Example 9A | ...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298315(US11547687, Example 11-1 | US10744104, Example 10 ...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582695(US11547687, Example 11-4)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582847(US11547687, Comparative Compound I | US20230285340...)
Affinity DataKi:  3.98nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582636(US11547687, Compound 21a)
Affinity DataIC50: 5nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582843(US11547687, Comparative Compound F | US20230285340...)
Affinity DataKi:  6.31nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582724(US11547687, Comparative Compound A | US20230285340...)
Affinity DataKi:  6.31nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50034842((2R,4S)-5-Biphenyl-4-yl-4-(3-carboxy-propionylamin...)
Affinity DataKi:  6.31nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298284(US10123984, Example 1 | (R)-5-Biphenyl-4-yl-2-hydr...)
Affinity DataKi:  12.6nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582640(US11547687, Compound 21d)
Affinity DataIC50: 27nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298320(US10123984, Example 12 | 3-(N-Biphenyl-4-ylmethyl-...)
Affinity DataKi:  35.5nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298290(US10744104, Example 2J | US10123984, Example 2J | ...)
Affinity DataKi:  35.5nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
US Patent

Displayed 1 to 50 (of 62 total ) | Next | Last >>
Jump to: